Published in Am J Transplant on March 16, 2015
HLA high-resolution typing for sensitized patients: a solution in search of a problem? Am J Transplant (2015) 1.58
cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator. Am J Transplant (2015) 0.85
Virtual HLA Crossmatching as a Means to Safely Expedite Transplantation of Imported Pancreata. Transplantation (2016) 0.76
Some considerations on the current debate about typing resolution in solid organ transplantation. Transplant Res (2016) 0.76
Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 0.76
The Humoral Theory of Transplantation: Epitope Analysis and the Pathogenicity of HLA Antibodies. J Immunol Res (2016) 0.75
The Association Between Broad Antigen HLA Mismatches, Eplet HLA Mismatches and Acute Rejection After Kidney Transplantation. Transplant Direct (2016) 0.75
Reflections on HLA Epitope-Based Matching for Transplantation. Front Immunol (2016) 0.75
Performance of an allele-level multi-locus HLA genotype imputation tool in hematopoietic stem cell donors from Quebec. Immun Inflamm Dis (2017) 0.75
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Kidney transplantation under FK 506. JAMA (1990) 7.45
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood (1997) 5.04
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem (1973) 4.44
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat Genet (2001) 3.86
The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med (2001) 3.85
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody. Proc Natl Acad Sci U S A (1984) 3.14
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Identification of a human T lymphocyte surface protein associated with the E-rosette receptor. J Exp Med (1981) 3.06
Deamination of cytosine derivatives by bisulfite. Mechanism of the reaction. J Am Chem Soc (1974) 2.92
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. Nature (1982) 2.84
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol Cell Biol (1986) 2.76
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Phylogeny and classification of the Digenea (Platyhelminthes: Trematoda). Int J Parasitol (2003) 2.72
Medical education and health for all. Aust J Public Health (1995) 2.65
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45
The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation (1984) 2.45
Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet (2001) 2.44
Structural model of HLA-DR1 restricted T cell antigen recognition. Cell (1988) 2.41
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
Functional, biochemical and genetic diversity of prokaryotic nitrate reductases. Cell Mol Life Sci (2001) 2.34
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The deamination of cytidine and cytosine by acidic buffer solutions. Mutagenic implications. Biochemistry (1966) 2.30
Antigen-specific human T lymphocyte clones: induction, antigen specificity, and MHC restriction of influenza virus-immune clones. J Immunol (1982) 2.30
Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells. J Exp Med (1994) 2.29
Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J (1999) 2.28
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
The detailed distribution of MHC Class II antigens in normal human organs. Transplantation (1984) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
On the reaction of guanine with glyoxal, pyruvaldehyde, and kethoxal, and the structure of the acylguanines. A new synthesis of N2-alkylguanines. Biochemistry (1969) 2.25
Overview: deinstitutionalization of psychiatric patients, a critical review of outcome studies. Am J Psychiatry (1981) 2.24
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Ultrastructural and biochemical changes in human jejunal mucosa associated with enteropathogenic Escherichia coli (0111) infection. J Pediatr Gastroenterol Nutr (1986) 2.21
Comparative pathology of the diseases caused by Hendra and Nipah viruses. Microbes Infect (2001) 2.21
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec (2001) 2.18
Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol (1991) 2.17
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant (2010) 2.14
HLA-DRB1 and multiple sclerosis in Malta. Neurology (2007) 2.14
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Characteristic ribonucleolytic activity of human angiogenin. Biochemistry (1986) 2.06
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant (2014) 2.00
Pancreas transplantation from donors after circulatory death from the United Kingdom. Am J Transplant (2012) 2.00
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. Am J Transplant (2013) 1.99
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93